Updates About Trending Searches From Various Sources Across the United States (USA) Now (Image or Photo Content)
Astrazeneca Asthma. Astrazeneca s azn asthma drug meets primary goal in phase iii. Compass a 6 month double blind double dummy randomised parallel group study compared the safety and efficacy of symbicort for maintenance and relief with salmeterol fluticasone and a fixed maintenance dose of symbicort both with terbutaline for relief.
In the study fasenra was effective in treating the size of nasal polyps and nasal blockage in patients with chronic rhinosinusitis with nasal polyps the company said. Astrazeneca plc on tuesday reported positive results from its phase 3 trial of tezepelumab a potential treatment for patients with severe uncontrolled asthma. Reuters astrazeneca plc said on thursday its asthma treatment for a chronic inflammatory disease of the nasal passage linings or sinuses met main goals in a late stage study.
Currently our respiratory biologics portfolio includes one recently approved medicine for the treatment of severe eosinophilic asthma with numerous regulatory decisions pending in additional.
Astrazeneca s azn pipeline candidate tezepelumab achieves the primary goal in phase iii navigator study for addressing patients with severe uncontrolled asthma. Nov 11 2020 11 48am est. Astrazeneca plc azn. Building on a 50 year heritage in respiratory care our ambition is to transform the treatment of asthma and chronic obstructive pulmonary disease copd by driving earlier biology led treatment eliminating preventable asthma attacks and removing copd as a top three leading cause of death.